Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

It’s not a coincidence that Pfizer, Lilly, Amgen, and AbbVie are all hawking anti-CGRP migraine drugs on their direct-to-consumer portals; these drugs don’t work well enough to be popular ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...